Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Qiaoyang Lu"'
Autor:
Henry Miles Prince, Chunrui Li, Hongmei Jing, Fang Ren, Zhen Cai, Li Bao, Peter Tan, Sorab Jehangir Shavaksha, Qingsong Yin, Peilong Lai, Qiumei Deng, Mingfei Zhang, Shuqi Zeng, Qiaoyang Lu, Chengjun Jiang, Danqing Wu, Jianqing Mi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 2 (2023)
Externí odkaz:
https://doaj.org/article/996d531be5074facbfeb0869e3e8f967
Autor:
Alexander E. Perl, Naoko Hosono, Pau Montesinos, Nikolai Podoltsev, Giovanni Martinelli, Nicki Panoskaltsis, Christian Recher, Catherine C. Smith, Mark J. Levis, Stephen Strickland, Christoph Röllig, Marco Groß-Langenhoff, Wen-Chien Chou, Je-Hwan Lee, Hisayuki Yokoyama, Nahla Hasabou, Qiaoyang Lu, Ramon V. Tiu, Jessica K. Altman
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 5, Pp 1-9 (2022)
Abstract The fms-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib is indicated for relapsed or refractory (R/R) FLT3-mutated acute myeloid leukemia (AML), based on its observed superior response and survival outcomes compared with salvage chemoth
Externí odkaz:
https://doaj.org/article/177517e470014866a24e2133dc705fd7
Autor:
Mikiko Kusano, Shin ichiro Fujiwara, Takayuki Shimizu, Masahiro Kizaki, Junya Kuroda, Kensuke Usuki, Erhan Berrak, Miho Nara, Shuichi Miyawaki, Tomoki Naoe, Kiyoshi Ando, Yoshinobu Maeda, Nobuyuki Aotsuka, Nahla Hasabou, Yukio Kobayashi, Qiaoyang Lu, Takayuki Ishikawa, Hisayuki Yokoyama, Tomoko Hata, Shigeru Chiba, Naoko Hosono, Masahiro Onozawa, Kohmei Kubo, Michihiro Hidaka, Yasuyoshi Morita, Hiroatsu Iida
Publikováno v:
International Journal of Clinical Oncology
Background Until recently, no effective targeted therapies for FLT3-mutated (FLT3mut+) relapsed/refractory (R/R) acute myeloid leukemia (AML) were available in Japan. The FLT3 inhibitor, gilteritinib, was approved in Japan for patients with FLT3mut+
Autor:
Alexander E Perl, Jessica K Altman, Naoko Hosono, Pau Montesinos, Nikolai Podoltsev, Giovanni Martinelli, Catherine C Smith, Mark J Levis, Christoph Röllig, Marco Groß-Langenhoff, Nahla Hasabou, Qiaoyang Lu, Ramon V Tiu
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S210
Autor:
Alexander E Perl, Jessica K Altman, Naoko Hosono, Pau Montesinos, Nikolai Podoltsev, Giovanni Martinelli, Catherine C Smith, Mark J Levis, Christoph Röllig, Marco Groß-Langenhoff, Nahla Hasabou, Qiaoyang Lu, Ramon V Tiu
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S280
Autor:
Christoph Röllig, Ramon V. Tiu, Nahla Hasabou, Qiaoyang Lu, Giovanni Martinelli, Pau Montesinos, Nikolai A. Podoltsev, Marco Groß-Langenhoff, Mark J. Levis, Jessica K. Altman, Alexander E. Perl, Catherine C. Smith, Naoko Hosono
Publikováno v:
Blood. 136:22-23
Background: Gilteritinib is a FLT3 inhibitor with demonstrated efficacy and safety in patients with FLT3-mutated relapsed or refractory (R/R) AML. The efficacy of gilteritinib in patients with prior tyrosine kinase inhibitor (TKI) therapy is not clea
Publikováno v:
Blood. 136:42-43
Background: Gilteritinib is approved for patients (pts) with relapsed/refractory (R/R) FLT3-mutated acute myeloid leukemia (AML), based on findings from the phase 3 ADMIRAL trial (Perl AE, et al. N Engl J Med. 2019). A phase 3 trial, QuANTUM-R, demon
Autor:
Tara L. Lin, Gary J. Schiller, Ramon V. Tiu, Jason Hill, Nikolai A. Podoltsev, Angela James, Brenda W. Cooper, Joseph G. Jurcic, Mohamad Cherry, Mark J. Levis, Qiaoyang Lu, Jose C. Cruz, Keith W. Pratz, Jessica K. Altman, Alexander E. Perl
Publikováno v:
Blood. 136:16-17
Background: Gilteritinib, an oral FMS-like tyrosine kinase 3 (FLT3) inhibitor, demonstrated antileukemic responses in patients with FLT3-mutated (FLT3mut+) relapsed/refractory acute myeloid leukemia (AML). We report final results from a phase 1 study
Autor:
Sung-Soo Yoon, Mark J. Levis, Pau Montesinos, Andreas Neubauer, Nikolai A. Podoltsev, Ramon V. Tiu, Hee-Je Kim, Jorge Sierra, Masahiro Onozawa, Shigeru Chiba, Nahla Hasabou, Giovanni Martinelli, Eunice S. Wang, Alexander E. Perl, Richard A. Larson, Qiaoyang Lu, Stephen A. Strickland, Gary J. Schiller, Christian Recher, Naoko Hosono
Publikováno v:
Journal of Clinical Oncology. 39:7013-7013
7013 Background: The phase 3 ADMIRAL trial demonstrated the superiority of gilteritinib to salvage chemotherapy (SC) in patients (pts) with FLT3-mutated ( FLT3mut+) R/R AML. Aim/Objective: A follow-up of ADMIRAL assessed long-term survivors, transpla
Autor:
David R. Andes, Christopher Lademacher, A. S. Henriksen, Mark E. Jones, Pranab K. Mukherjee, William W. Hope, Laura L. Kovanda, Qiaoyang Lu, Mahmoud A. Ghannoum
Publikováno v:
Antimicrobial Agents and Chemotherapy
This pooled analysis evaluated the relationship of isavuconazole and voriconazole MICs of Aspergillus pathogens at baseline with all-cause mortality and clinical outcomes following treatment with either drug in the SECURE and VITAL trials. Isavuconaz